Dose Ranging Study to Evaluate the Efficacy and Safety of MEDI8852 in Adults Who Are Hospitalized With Type A Influenza.

PHASE2WithdrawnINTERVENTIONAL

Timeline

Start Date

July 24, 2017

Primary Completion Date

July 26, 2019

Study Completion Date

July 26, 2019

Conditions

Influenza - Type A Strains

Interventions

DRUG

Oseltamivir

Standard of care for influenza caused by Type A strains

DRUG

MEDI8852

MEDI8852 is a human IgG1 kappa monoclonal antibody (mAb) administered via infusion.

DRUG

Placebo

Salt-water solution containing no active ingredients.